PURPOSE/ OBJECTIVES: To determine whether improved monitoring through close follow-up with a nurse practitioner (NP) could enhance treatment compliance and decrease frequency of hospitalizations. DESIGN: Retrospective chart review. SETTING: An academic National Cancer Institute-designated comprehensive cancer center. SAMPLE: 151 patients aged 45-65 years diagnosed with stage III or IV oropharyngeal cancer. METHODS: Patients were nonrandomized to one of two groups: a prechemotherapy clinic group and a weekly NP-led clinic group. After examination of descriptive statistics, multiple linear and logistic regressions were used to compare groups across patient outcomes. MAIN RESEARCH VARIABLES: Hospitalization, chemotherapy dose deviations, and chemotherapy treatment completion. FINDINGS: The average number of visits during traditional treatment was three and, after initiation of the NP-led clinic, the number was six. The hospitalization rate was 28% in the traditional clinic group compared to 12% in the NP-led group. The rate of chemotherapy dose deviations was 48% in the traditional clinic group compared to 6% in the NP-led clinic group. Forty-six percent of patients in the traditional clinic group received the full seven scheduled doses of chemotherapy compared to 90% of patients seen in the NP-led clinic group. CONCLUSIONS: A weekly NP-led symptom management clinic reduces rates of hospitalization and chemotherapy dose deviations and increases chemotherapy completion in patients receiving intensive chemoradiotherapy for oropharyngeal cancer. IMPLICATIONS FOR NURSING: Patients receiving chemoradiotherapy benefit from close monitoring for toxicities by NPs to successfully complete their treatment and avoid hospitalization. KNOWLEDGE TRANSLATION: Early interventions to manage toxicities in patients with head and neck cancer can improve outcomes. NPs are in a key position to manage these toxicities and, when symptoms are controlled, costs are reduced.
PURPOSE/ OBJECTIVES: To determine whether improved monitoring through close follow-up with a nurse practitioner (NP) could enhance treatment compliance and decrease frequency of hospitalizations. DESIGN: Retrospective chart review. SETTING: An academic National Cancer Institute-designated comprehensive cancer center. SAMPLE: 151 patients aged 45-65 years diagnosed with stage III or IV oropharyngeal cancer. METHODS:Patients were nonrandomized to one of two groups: a prechemotherapy clinic group and a weekly NP-led clinic group. After examination of descriptive statistics, multiple linear and logistic regressions were used to compare groups across patient outcomes. MAIN RESEARCH VARIABLES: Hospitalization, chemotherapy dose deviations, and chemotherapy treatment completion. FINDINGS: The average number of visits during traditional treatment was three and, after initiation of the NP-led clinic, the number was six. The hospitalization rate was 28% in the traditional clinic group compared to 12% in the NP-led group. The rate of chemotherapy dose deviations was 48% in the traditional clinic group compared to 6% in the NP-led clinic group. Forty-six percent of patients in the traditional clinic group received the full seven scheduled doses of chemotherapy compared to 90% of patients seen in the NP-led clinic group. CONCLUSIONS: A weekly NP-led symptom management clinic reduces rates of hospitalization and chemotherapy dose deviations and increases chemotherapy completion in patients receiving intensive chemoradiotherapy for oropharyngeal cancer. IMPLICATIONS FOR NURSING: Patients receiving chemoradiotherapy benefit from close monitoring for toxicities by NPs to successfully complete their treatment and avoid hospitalization. KNOWLEDGE TRANSLATION: Early interventions to manage toxicities in patients with head and neck cancer can improve outcomes. NPs are in a key position to manage these toxicities and, when symptoms are controlled, costs are reduced.
Authors: Jennifer M Hinkel; Jonathan L Vandergrift; Sara J Perkel; Marcy B Waldinger; William Levy; F Marc Stewart Journal: J Oncol Pract Date: 2010-06-23 Impact factor: 3.840
Authors: Robin P Newhouse; Julie Stanik-Hutt; Kathleen M White; Meg Johantgen; Eric B Bass; George Zangaro; Renee F Wilson; Lily Fountain; Donald M Steinwachs; Lou Heindel; Jonathan P Weiner Journal: Nurs Econ Date: 2011 Sep-Oct Impact factor: 1.085
Authors: Robert P Takes; Primož Strojan; Carl E Silver; Patrick J Bradley; Missak Haigentz; Gregory T Wolf; Ashok R Shaha; Dana M Hartl; Jan Olofsson; Johannes A Langendijk; Alessandra Rinaldo; Alfio Ferlito Journal: Head Neck Date: 2010-11-10 Impact factor: 3.147
Authors: William Bensinger; Mark Schubert; Kie-Kian Ang; David Brizel; Elizabeth Brown; June G Eilers; Linda Elting; Bharat B Mittal; Mark A Schattner; Ricardo Spielberger; Nathaniel S Treister; Andy M Trotti Journal: J Natl Compr Canc Netw Date: 2008-01 Impact factor: 11.908
Authors: Ruth McCorkle; Michael Dowd; Elizabeth Ercolano; Dena Schulman-Green; Anna-leila Williams; Mary Lou Siefert; Jeanne Steiner; Peter Schwartz Journal: Psychooncology Date: 2009-01 Impact factor: 3.894
Authors: Mary Wells; Peter T Donnan; Lena Sharp; Caroline Ackland; Janice Fletcher; John A Dewar Journal: J Clin Nurs Date: 2007-12-18 Impact factor: 3.036
Authors: Narissa J Nonzee; Neal A Dandade; Urjeet Patel; Talar Markossian; Mark Agulnik; Athanassios Argiris; Jyoti D Patel; Robert C Kern; Hidayatullah G Munshi; Elizabeth A Calhoun; Charles L Bennett Journal: Cancer Date: 2008-09-15 Impact factor: 6.860
Authors: Andrea L Cheville; Steven R Alberts; Teresa A Rummans; Jeffrey R Basford; Maria I Lapid; Jeff A Sloan; Daniel V Satele; Matthew M Clark Journal: J Pain Symptom Manage Date: 2015-05-12 Impact factor: 3.612
Authors: Heidi Mason; Mary Beth DeRubeis; Nancy Burke; Melissa Shannon; Danielle Karsies; Gregory Wolf; Avi Eisbruch; Francis Worden Journal: World J Clin Oncol Date: 2016-04-10
Authors: Clark DuMontier; Mina S Sedrak; Wee Kheng Soo; Cindy Kenis; Grant R Williams; Kristen Haase; Magnus Harneshaug; Hira Mian; Kah Poh Loh; Siri Rostoft; William Dale; Harvey Jay Cohen Journal: J Geriatr Oncol Date: 2019-08-23 Impact factor: 3.599
Authors: Hans Wildiers; Pieter Heeren; Martine Puts; Eva Topinkova; Maryska L G Janssen-Heijnen; Martine Extermann; Claire Falandry; Andrew Artz; Etienne Brain; Giuseppe Colloca; Johan Flamaing; Theodora Karnakis; Cindy Kenis; Riccardo A Audisio; Supriya Mohile; Lazzaro Repetto; Barbara Van Leeuwen; Koen Milisen; Arti Hurria Journal: J Clin Oncol Date: 2014-08-20 Impact factor: 44.544